Obsidian Therapeutics Announces Closing of $115 Million Series B Financing

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Sept. 9, 2021 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a $115 million Series B financing with a premier syndicate of life science investors led by The Column Group Crossover Fund (TCGX). Additional new...

Click to view original post